Search hospitals > Illinois > Chicago
University of Illinois at Chicago
Claim this profileChicago, Illinois 60612
Global Leader in Thyroid Cancer
Global Leader in Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Breast Cancer
Conducts research for Lymphoma
906 reported clinical trials
63 medical researchers
Summary
University of Illinois at Chicago is a medical facility located in Chicago, Illinois. This center is recognized for care of Thyroid Cancer, Cancer, T-Lymphoblastic Leukemia/Lymphoma, Breast Cancer, Lymphoma and other specialties. University of Illinois at Chicago is involved with conducting 906 clinical trials across 1,200 conditions. There are 63 research doctors associated with this hospital, such as Mary L. Schmidt, Lawrence E. Feldman, Peter Riedell, MD, and Shikha Jain.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Mary L. SchmidtUniversity of Illinois7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
48 reported clinical trials
99 drugs studied
Lawrence E. FeldmanUniversity of Illinois6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
30 reported clinical trials
42 drugs studied
Peter Riedell, MDUniversity of Chicago7 years of reported clinical research
Expert in Lymphoma
Studies B-Cell Lymphoma
16 reported clinical trials
27 drugs studied
Shikha JainUniversity of Illinois6 years of reported clinical research
Studies Stomach Cancer
Studies Thyroid Cancer
15 reported clinical trials
31 drugs studied
Clinical Trials running at University of Illinois at Chicago
Lung Cancer
Prostate Cancer
Breast Cancer
Thyroid Cancer
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Breast cancer
Kidney Cancer
Stomach Cancer
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
Sotorasib Combo vs Pembrolizumab Combo
for Advanced Lung Cancer
This trial is testing two different drug combinations with chemotherapy to see which helps cancer patients live longer without their disease getting worse. One combination includes sotorasib, which targets cancer mutations, and the other includes pembrolizumab, which helps the immune system fight cancer. Pembrolizumab has been shown to improve overall survival in various cancers when combined with chemotherapy.
Recruiting2 awards Phase 33 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Illinois at Chicago?
Where is University of Illinois at Chicago located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Illinois at Chicago accept?
What awards or recognition has University of Illinois at Chicago received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.